AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10526823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 10526823 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 8661571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 60
Study 8661571 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine methyl bromide (SMB)
Number of subjects: 60
Study 2071787 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 (10 mg)
Number of subjects: 12
Study 2071787 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 (40 mg)
Number of subjects: 12
Study 2071787 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB 2086 (100 mg)
Number of subjects: 12
Study 2071787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6223692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloromethylene diphosphonate (Cl2MDP)
Number of subjects: 0
Study 6223692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30959274 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help stress management intervention (workbook based on an integrative stress model framework)
Number of subjects: 82
Study 30959274 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 82
Study 29444787 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge follow-up phone call
Number of subjects: 0
Study 26472752 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 2000 mg
Number of subjects: 80
Study 26472752 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg
Number of subjects: 80
Study 23775545 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial reanimation surgery
Number of subjects: 90
Study 22777298 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 91
Study 22777298 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 91
Study 20420663 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal survey technique including semi-structured questionnaires, breath alcohol test, drug assumption tests, and reaction time measurement using a driving simulator.
Number of subjects: 5000
Study 18538773 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.75% ropivacaine
Number of subjects: 100
Study 18538773 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 15660437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score
Number of subjects: 80
Study 15660437 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasound
Number of subjects: 80
Study 15660437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score and Transvaginal ultrasound
Number of subjects: 80
Study 12687331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 552
Study 11146613 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 0
Study 11146613 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 9333593 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 0
Study 9333593 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium treatment
Number of subjects: 0
Study 9333593 — intervention group
Group type: COMPARATOR
Intervention: Magnesium application
Number of subjects: 0
Study 8316579 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training at 30 degrees knee flexion
Number of subjects: 107
Study 8316579 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training at 60 degrees knee flexion
Number of subjects: 107
Study 8316579 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training at 90 degrees knee flexion
Number of subjects: 107
Study 8316579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 107
Study 3551602 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean dose, 79.6 mg per day)
Number of subjects: 100
Study 3551602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (mean dose, 198.4 mg per day)
Number of subjects: 100
Study 30316590 — intervention group
Group type: COMPARATOR
Intervention: 90:10 treatment (extruded high-fat pellet mixed with low-fat control pellet)
Number of subjects: 75
Study 30316590 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded high-fat pellet inclusion
Number of subjects: 75
Study 30316590 — intervention group
Group type: EXPERIMENTAL
Intervention: 80:20 treatment
Number of subjects: 75
Study 30316590 — intervention group
Group type: COMPARATOR
Intervention: 70:30 treatment, HFSP, and control
Number of subjects: 75
Study 30316590 — intervention group
Group type: COMPARATOR
Intervention: 90:10 treatment
Number of subjects: 75
Study 30316590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat inclusion (7% total fat)
Number of subjects: 75
Study 28060791 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with prebiotics (FOS and GOS)
Number of subjects: 182
Study 28060791 — intervention group
Group type: COMPARATOR
Intervention: Infant formula supplemented with synbiotics (FOS/GOS and Lactobacillus paracasei ssp. paracasei strain F19)
Number of subjects: 182
Study 26022195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure™ hemorrhoidectomy (Group 1, n = 26)
Number of subjects: 54
Study 26022195 — intervention group
Group type: COMPARATOR
Intervention: Milligan Morgan hemorrhoidectomy (Group 2, n = 28)
Number of subjects: 54
Study 23273974 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cost display group (5 imaging tests)
Number of subjects: 10
Study 23273974 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 imaging tests)
Number of subjects: 10
Study 23273974 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cost display group
Number of subjects: 10
Study 23273974 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 21624240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil supplementation (0.5 g every 15 days for six times)
Number of subjects: 100
Study 21624240 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 100
Study 18056271 — intervention group
Group type: EXPERIMENTAL
Intervention: FPV-RTV (700/100 mg BID) with 75% reduced RFB dose (150 mg QOD)
Number of subjects: 22
Study 18056271 — intervention group
Group type: COMPARATOR
Intervention: RFB (300 mg QD)
Number of subjects: 22
Study 18056271 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 22
Study 16416154 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (2x36 mg daily)
Number of subjects: 55
Study 16416154 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin/warfarin
Number of subjects: 55
Study 16416154 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran (2x24 mg daily)
Number of subjects: 55
Study 16416154 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 12789901 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinformation presented by a partner during memory recall
Number of subjects: 0
Study 10832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate information presented by a partner during memory recall
Number of subjects: 0
Study 10832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of crime with a partner who saw a slightly different sequence
Number of subjects: 0
Study 10832514 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence ratings of participants
Number of subjects: 0
Study 9356766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water (0.5 degree C; trial CD26)
Number of subjects: 7
Study 9356766 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool water (19 degrees C; trial CL26)
Number of subjects: 7
Study 9356766 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion (any temperature)
Number of subjects: 7
Study 8449013 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral mifepristone
Number of subjects: 13
Study 8449013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31208815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, thalidomide, and dexamethasone with daratumumab
Number of subjects: 0
Study 31208815 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib, thalidomide, and dexamethasone without daratumumab
Number of subjects: 0
Study 31308305 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic blood cardioplegia (IBC)
Number of subjects: 48
Study 31308305 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic blood cardioplegia (HBC)
Number of subjects: 48
Study 27663190 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g TXA intraoperative injection
Number of subjects: 198
Study 27663190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 198
Study 27111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised audiology report
Number of subjects: 32
Study 27111466 — intervention group
Group type: COMPARATOR
Intervention: Unrevised audiology report
Number of subjects: 32
Study 24356481 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + placebo
Number of subjects: 0
Study 24356481 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 0
Study 24356481 — intervention group
Group type: COMPARATOR
Intervention: golimumab
Number of subjects: 0
Study 24356481 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 0
Study 22661243 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/d fish oil (GA)
Number of subjects: 41
Study 22661243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d fish oil (GB)
Number of subjects: 41
Study 22661243 — intervention group
Group type: COMPARATOR
Intervention: Control (GC)
Number of subjects: 41
Study 20833940 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of orally-disintegrating olanzapine
Number of subjects: 495
Study 20833940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 17008098 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 2
Study 17008098 — intervention group
Group type: COMPARATOR
Intervention: Natural history (control)
Number of subjects: 2
Study 16282288 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-Pyrimethamine (AQ + SP)
Number of subjects: 944
Study 16282288 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 944
Study 16282288 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 944
Study 12110113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 0
Study 12110113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 1 mg
Number of subjects: 0
Study 12110113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 0
Study 12110113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9854511 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-SAM2, MCNU, and radiotherapy (TMR group)
Number of subjects: 40
Study 9854511 — intervention group
Group type: COMPARATOR
Intervention: MCNU and radiotherapy (MR group)
Number of subjects: 40
Study 7832333 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg ondansetron
Number of subjects: 130
Study 7832333 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/kg ondansetron
Number of subjects: 130
Study 7832333 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg ondansetron
Number of subjects: 130
Study 7832333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 2186276 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment unit
Number of subjects: 155
Study 2186276 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 155
Study 355661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bethanechol chloride (25 mg)
Number of subjects: 0
Study 355661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bethanechol chloride (50 mg)
Number of subjects: 0
Study 355661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bethanechol chloride (100 mg)
Number of subjects: 0
Study 355661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30269231 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthMpowerment.org (HMP) online intervention
Number of subjects: 474
Study 30269231 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthMpowerment.org (HMP) online intervention (for those using it for over 60 min)
Number of subjects: 474
Study 30269231 — intervention group
Group type: COMPARATOR
Intervention: Information-only control website
Number of subjects: 474
Study 29522897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary behavioral intervention (PPACT) in conjunction with current health care services
Number of subjects: 0
Study 29522897 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29522897 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary behavioral intervention (PPACT)
Number of subjects: 0
Study 26397405 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stent (EES)
Number of subjects: 500
Study 26397405 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 500
Study 25153313 — intervention group
Group type: EXPERIMENTAL
Intervention: Preg CHAT (tailored SMS-texting intervention)
Number of subjects: 35
Study 25153313 — intervention group
Group type: COMPARATOR
Intervention: Txt4Baby (generic texting intervention)
Number of subjects: 35
Study 22105435 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 126
Study 22105435 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 126
Study 19149706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution heart rate variability (HRV) analysis
Number of subjects: 273
Study 19149706 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution HRV analysis
Number of subjects: 273
Study 19149706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 273
Study 17488381 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-ST group
Number of subjects: 430
Study 17488381 — intervention group
Group type: COMPARATOR
Intervention: SRL-CsA-ST group
Number of subjects: 430
Study 17488381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 430
Study 15114342 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Amphetamine (AMPH) 0.25 mg/kg
Number of subjects: 40
Study 15114342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11822611 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 16
Study 11822611 — intervention group
Group type: COMPARATOR
Intervention: Dummy acupuncture
Number of subjects: 16
Study 11822611 — intervention group
Group type: COMPARATOR
Intervention: Mock transelectrical nerve stimulation (TENS)
Number of subjects: 16
Study 9627189 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) combined with noxious finger stimulation at an interstimulus interval of 100 ms
Number of subjects: 5
Study 9627189 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) applied alone
Number of subjects: 5
Study 8002646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide and tetracycline (500 mg nicotinamide three times daily, 500 mg tetracycline four times daily)
Number of subjects: 20
Study 8002646 — intervention group
Group type: COMPARATOR
Intervention: Prednisone therapy
Number of subjects: 20
Study 2562200 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS (Y set with two short branches filled with electrolytic chloroxidizer solution)
Number of subjects: 60
Study 2562200 — intervention group
Group type: COMPARATOR
Intervention: TCS (traditional Y set)
Number of subjects: 60
Study 2562200 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS
Number of subjects: 60
Study 2562200 — intervention group
Group type: COMPARATOR
Intervention: TCS
Number of subjects: 60
Study 31974091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-ring circular plastic wound protector with circular polyethylene drape
Number of subjects: 458
Study 31974091 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical dressing gauze
Number of subjects: 458
Study 29233169 — intervention group
Group type: COMPARATOR
Intervention: SIGMA mHealth intervention (gamified mobile application based on CBT principles) for 2 months with a 3-month follow-up.
Number of subjects: 0
Study 25339155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue with a low concentration of thrombin (ARTISS, Baxter) applied under the abdominal flap
Number of subjects: 30
Study 25339155 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 30
Study 25339155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue with a low concentration of thrombin (ARTISS, Baxter)
Number of subjects: 30
Study 24384675 — intervention group
Group type: EXPERIMENTAL
Intervention: One-contact referral to locally organized physical activities
Number of subjects: 442
Study 24384675 — intervention group
Group type: EXPERIMENTAL
Intervention: One-contact provision of a walking program
Number of subjects: 442
Study 24384675 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week multiple-contact physical activity coaching based on the Self-Determination Theory
Number of subjects: 442
Study 24384675 — intervention group
Group type: COMPARATOR
Intervention: All programs
Number of subjects: 442
Study 24384675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 442
Study 21969261 — intervention group
Group type: EXPERIMENTAL
Intervention: GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, and 45 mg quercetin glycosides per day)
Number of subjects: 40
Study 21969261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21969261 — intervention group
Group type: EXPERIMENTAL
Intervention: GCQ supplement
Number of subjects: 40
Study 19351807 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (5 days/week, 60 min/day, 75% Vo(2 max)) combined with eucaloric diet (EX)
Number of subjects: 19
Study 19351807 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (5 days/week, 60 min/day, 75% Vo(2 max)) combined with hypocaloric diet (EX-HYPO)
Number of subjects: 19
Study 17207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex practices
Number of subjects: 2595
Study 17207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of feeding behaviour due to HIV concerns
Number of subjects: 2595
Study 17207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about own HIV status
Number of subjects: 2595
Study 17207153 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence to prevent HIV
Number of subjects: 2595
Study 17207153 — intervention group
Group type: EXPERIMENTAL
Intervention: No new HIV infections among abstaining single mothers
Number of subjects: 2595
Study 15241585 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance (CrCl) < 65 ml/min
Number of subjects: 186
Study 15241585 — intervention group
Group type: COMPARATOR
Intervention: Creatinine clearance (CrCl) >= 65 ml/min
Number of subjects: 186
Study 12452237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg x kg(‐1) and succinylcholine 1.5 mg x kg(‐1) (Group LS)
Number of subjects: 135
Study 12452237 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and succinylcholine 1.5 mg x kg(‐1) (Group PS)
Number of subjects: 135
Study 12452237 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline and rocuronium 0.6 mg x kg(‐1) (Group PR)
Number of subjects: 135
Study 10352377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mahonia aquifolium ointment
Number of subjects: 49
Study 10352377 — intervention group
Group type: COMPARATOR
Intervention: Dithranol
Number of subjects: 49
Study 8520743 — intervention group
Group type: COMPARATOR
Intervention: Antacids (30 mL every 4 h)
Number of subjects: 141
Study 8520743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every 4 h)
Number of subjects: 141
Study 8520743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 141
Study 8520743 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric acidity
Number of subjects: 141
Study 1770194 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200-kcal/day diet
Number of subjects: 12
Study 1770194 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% calorie-restricted diet (1600-1800 kcal/day)
Number of subjects: 12
Study 1770194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic insulin
Number of subjects: 12
Study 1770194 — intervention group
Group type: COMPARATOR
Intervention: 2400-kcal/day diet
Number of subjects: 12
Study 7060036 — intervention group
Group type: EXPERIMENTAL
Intervention: iv melphalan (16 mg/m2 every 2 weeks for four doses, followed by a single dose every 4 weeks)
Number of subjects: 295
Study 7060036 — intervention group
Group type: EXPERIMENTAL
Intervention: iv melphalan (50% dose reduction)
Number of subjects: 295
Study 7060036 — intervention group
Group type: EXPERIMENTAL
Intervention: oral melphalan (0.15 mg/kg/day for 7 days, followed by 0.05 mg/kg/day after recovery from the wbc count nadir)
Number of subjects: 295
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile based technology (e.g., Braille books, Braille slate and stylus)
Number of subjects: 250
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual based technology (e.g., video magnifiers)
Number of subjects: 250
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking canes
Number of subjects: 250
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Audible balls
Number of subjects: 250
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen readers
Number of subjects: 250